Will the market price of Axitinib decrease in 2025?

As of2025, the price of axitinib (Axitinib) in the Chinese market has not dropped significantly. The main reasons include national medical insurance policies, the development of the generic drug market and centralized drug procurement.

First of all, axitinib, as an imported original drug, has been included in China’s national medical insurance directory. However, due to its high price and limited medical insurance payment ratio, the patient's out-of-pocket portion is still relatively large. For example, the price of imported original drugs is about more than 4,000 yuan, and the reimbursement ratio of medical insurance may vary from region to region, resulting in patients' out-of-pocket expenses still being high.

Secondly, although generic axitinib drugs have been launched in China and are cheaper than the original drug, the price has not dropped significantly due to fierce competition in the generic drug market. For example, the price of generic drugs in India and Laos is around a few hundred yuan, but due to factors such as market demand and supply, the price has not yet been reduced further.

Finally, the centralized drug procurement policy has a limited impact on the price of axitinib. Due to its small sales in the Chinese market, it was not included in the scope of centralized procurement and therefore failed to enjoy the price concessions brought by centralized procurement. For example, other drugs may achieve price reductions of more than 90% during centralized purchasing, but axitinib failed to benefit from this policy.

To sum up, it is expected that the price of axitinib in the Chinese market will remain stable in2025 and it is difficult to see a significant decline in the short term. When patients choose medications, they should comprehensively consider factors such as drug price, efficacy, and medical insurance reimbursement to make reasonable decisions.

Reference materials:https://en.wikipedia.org/wiki/Axitinib